Drug
T-Guard
T-Guard is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_3
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 32 (66.7%)
Trials by Status
terminated267%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_3
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
NCT04934670
terminatedphase_3
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
NCT04128319
completedphase_1
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
NCT02027805
Clinical Trials (3)
Showing 3 of 3 trials
NCT04934670Phase 3
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
NCT04128319Phase 3
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
NCT02027805Phase 1
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3